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To evaluate nifedipine, all medications were stopped. Baseline
pulmonary artery pressure was 70/25 mm Hg and pulmonary vas-
cular resistance 797 dynes's'cm -5. Nifedipine was begun at a dose
of 10 mg orally and was increased by 10 mg every 6 hours until
40 mg every 6 hours was reached. In the report by Douglas,
increasing doses of nifedipine resulted in increasing hemodynamic
effect. In contrast, this patient had no hemodynamic response until
a dose of 40 mg was reached. At this dose, pulmonary vascular
resistance fell to 523 dynes's'cm- 5 with no decrease in pulmonary
artery pressure.
Two other points should be mentioned. First, vasodilators caused
a decrease in pulmonary vascular resistance, increase in cardiac
output and maintenance of the same pulmonary artery pressure.
Although Douglas discussed the possibility of disadvantages from
this type of response, the present patient did have symptomatic
improvement including elimination of syncope and reduction in
chest pain. Second, all vasodilators caused similar hemodynamic
and symptomatic responses. In this patient, the choice of vaso-
dilator agent seemed dictated more by side effects than by any
difference in hemodynamic response.
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Nifedipine-Phenytoin Interaction
In 1973, a 57 year old white man was diagnosed as having grand
mal epilepsy of undertermined origin. He was started on phenytoin,
300 mg daily, and his seizure disorder has been well under control
with serum phenytoin levels in the therapeutic range.
In early 1983, nifedipine, 30 mg a day, was instituted to control
his angina. After 3 weeks of treatment with nifedipine, he began
to experience tremors in both arms, severe headaches, extreme
restlessness, unsteadiness, insomnia, depression and panic. By the
fourth week of nifedipine therapy, the patient also had slurred
speech. Clinical examination revealed a frightened and depressed
man with nystagmus, dysarthria and cerebellar ataxia. A pre-
sumptive diagnosis of phenytoin toxicity due to an interaction was
made and nifedipine was stopped immediately. Complete blood
count and SMA-12 profile did not reveal any abnormality. The
serum phenytoin level was 30.4 JLg/ml.
Marked improvement was noted over the next 2 weeks when
the serum phenytoin level was noted to be 10.5 JLg/ml. Complete
resolution of all the symptoms took place over the next 2 weeks.
It appears that this patient had central nervous system toxicity,
probably related to phenytoin-nifedipine interaction.
Nifedipine is very highly protein-bound; therefore, it displaces
phenytoin, which is weakly bound to blood proteins. Nifedipine
may inhibit the parahydroxylation of phenytoin in the liver, thereby
increasing the serum levels of phenytoin to a point where signs of
phenytoin intoxication occur. The interrelation of these two drugs
appears to be rather complex.
Therefore, a drug may be exposed to the effects of interaction
at more than one site and more than one mechanism. Anticon-
vulsant drugs such as anticoagulant, antihypertensive, antidiabetic
and antianginal agents are used within a rigid sphere of patient
stabilization. Drug interaction, therefore, exerts a special hazard
in such cases. Schedules of dosage for phenytoin should be ap-
propriately adjusted to compensate for this clinically important
interaction.
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Correction
In the case report, "Origin of Both Coronary Arteries From
the Pulmonary Trunk Associated With Hypoplasia of the Aortic
Track Complex: A New Entity" by Bharati et al. (J Am Coli
Cardiol 1984;3:437-41) type was inadvertently dropped from the
fourth paragraph on page 440. The corrected paragraph should
read:
This takes us to our present case. In classic hypoplasia of the
aortic tract complex or hypoplastic left heart syndrome, there is
aortic atresia with mitral stenosis or atresia (19,20). This is as-
sociated with an atrial septal defect, but usually no ventricular
septal defect. The ascending aorta is minute, the transverse aorta
is somewhat smaller than normal and the descending aorta is nor-
mal in size. The ductus arteriosus is widely patent. When there is
mitral atresia, there is muscle representing the left ventricle but
no lumen to this ventricular mass. When there is mitral stenosis,
then there is a small left ventricle with endocardial fibroelastosis.
Our case is atypical in that there is a ventricular septal defect.
